|
1
|
Fecci PE, Heimberger AB and Sampson JH:
Immunotherapy for primary brain tumors: No longer a matter of
privilege. Clin Cancer Res. 20:5620–5629. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stewart LA: Chemotherapy in adult
high-grade glioma: A systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet.
359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Claus EB, Walsh KM, Wiencke JK, Molinaro
AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R and
Wrensch M: Survival and low-grade glioma: The emergence of genetic
information. Neurosurg Focus. 38:E62015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boiardi A, Bartolomei M, Silvani A, Eoli
M, Salmaggi A, Lamperti E, Milanesi I, Botturi A, Rocca P, Bodei L,
et al: Intratumoral delivery of mitoxantrone in association with
90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J
Neurooncol. 72:125–131. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moretta L, Locatelli F, Pende D, Marcenaro
E, Mingari MC and Moretta A: Killer Ig-like receptor-mediated
control of natural killer cell alloreactivity in haploidentical
hematopoietic stem cell transplantation. Blood. 117:764–771. 2011.
View Article : Google Scholar
|
|
6
|
Leung W, Iyengar R, Turner V, Lang P,
Bader P, Conn P, Niethammer D and Handgretinger R: Determinants of
antileukemia effects of allogeneic NK cells. J Immunol.
172:644–650. 2004. View Article : Google Scholar
|
|
7
|
Igarashi T, Wynberg J, Srinivasan R,
Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM,
Caligiuri MA and Childs RW: Enhanced cytotoxicity of allogeneic NK
cells with killer immunoglobulin-like receptor ligand
incompatibility against melanoma and renal cell carcinoma cells.
Blood. 104:170–177. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu T, Zhang C, Tian Z, Wang J, Zhang J and
Sun R: Preliminary study in purification, proliferation and cloning
of human NK cells. Shanghai Mian Yi Xue Za Zhi. 20:148–151. 2000.In
Chinese.
|
|
9
|
Rossjohn J, Pellicci DG, Patel O, Gapin L
and Godfrey DI: Recognition of CD1d-restricted antigens by natural
killer T cells. Nat Rev Immunol. 12:845–857. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Zhang JH, Xu XQ, Feng JB, Sun N
and Tiang ZG: The characterization of NK-92 cell line transfected
with human stem cell factor gene. Zhong Guo Zhong Liu Sheng Wu Zhi
Liao Za Zhi Bian Ji Bu. 10:21–24. 2003.In Chinese.
|
|
11
|
Wilson JL, Charo J, Martín-Fontecha A,
Dellabona P, Casorati G, Chambers BJ, Kiessling R, Bejarano MT and
Ljunggren HG: NK cell triggering by the human costimulatory
molecules CD80 and CD86. J Immunol. 163:4207–4212. 1999.PubMed/NCBI
|
|
12
|
Farag SS, Fehniger TA, Ruggeri L, Velardi
A and Caligiuri MA: Natural killer cell receptors: New biology and
insights into the graft-versus-leukemia effect. Blood.
100:1935–1947. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chalupny NJ, Sutherland CL, Lawrence WA,
Rein-Weston A and Cosman D: ULBP4 is a novel ligand for human
NKG2D. Biochem Biophys Res Commun. 305:129–135. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vitale M, Cantoni C, Pietra G, Mingari MC
and Moretta L: Effect of tumor cells and tumor microenvironment on
NK-cell function. Eur J Immunol. 44:1582–1592. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kazimer RM, Whisler RL, Stephens RE, Pearl
DK and Yates AJ: Sensitivity of glioma and fetal brain cell lines
to natural killer cytolysis in a monolayer assay. J Neurooncol.
7:145–150. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sivori S, Parolini S, Marcenaro E,
Castriconi R, Pende D, Millo R and Moretta A: Involvement of
natural cytotoxicity receptors in human natural killer
cell-mediated lysis of neuroblastoma and glioblastoma cell lines. J
Neurooncol. 107:220–225. 2000.
|
|
17
|
Ghadially H, Ohana M, Elboim M, Gazit R,
Gur C, Nagler A and Mandelboim O: NK cell receptor NKp46 regulates
graft-versus-Host disease. Cell Rep. 7:1809–1814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisele G, Wischhusen J, Mittelbronn M,
Meyermann R, Waldhauer I, Steinle A, Weller M and Friese MA:
TGF-beta and metalloproteinases differentially suppress NKG2D
ligand surface expression on malignant glioma cells. Brain.
129:2416–2425. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu A, Wiesner S, Xiao J, Ericson K, Chen
W, Hall WA, Low WC and Ohlfest JR: Expression of MHC I and NK
ligands on human CD133(+) glioma cells: Possible targets of
immunotherapy. J Neurooncol. 83:121–131. 2007. View Article : Google Scholar
|
|
20
|
Ishikawa E, Tsuboi K, Saijo K, Harada H,
Takano S, Nose T and Ohno T: Autologous natural killer cell therapy
for human recurrent malignant glioma. Anticancer Res. 24:1861–1871.
2004.PubMed/NCBI
|
|
21
|
Avril T, Vauleon E, Hamlat A, Saikali S,
Etcheverry A, Delmas C, Diabira S, Mosser J and Quillien V: Human
glioblastoma stem-like cells are more sensitive to allogeneic NK
and T cell-mediated killing compared with serum-cultured
glioblastoma cells. Brain Pathol. 22:159–174. 2012. View Article : Google Scholar
|
|
22
|
Iovino F, Meraviglia S, Spina M, Orlando
V, Saladino V, Dieli F, Stassi G and Todaro M: Immunotherapy
targeting colon cancer stem cells. Immunotherapy. 3:97–106. 2011.
View Article : Google Scholar
|
|
23
|
Qi Y, Li RM, Kong FM, Li H, Yu JP and Ren
XB: How do tumor stem cells actively escape from host
immunosurveillance? Biochem Biophys Res Commun. 420:699–703. 2012.
View Article : Google Scholar : PubMed/NCBI
|
